ā† Back

Vericel: Vericel Corporation's Strong Q4 2025 Results and Promising 2026 Outlook

Vericel Corporation reported a robust fourth quarter 2025 with record total revenue of $92.9 million, a 23% increase from the previous year, driven primarily by the strong performance of its MACI product. MACI revenue reached $84.1 million, representing a 23% year-over-year growth and a 51% sequential growth from the third quarter. The company's gross margin was nearly 80%, and the adjusted EBITDA margin was 40% for the quarter. For the full year 2025, total revenue was $276.3 million, with MACI revenue at $239.5 million, a 21% increase. The actual EPS for the quarter was $0.45, in line with analyst estimates. The company's financial performance was highlighted by a significant expansion in its sales force by 30% in the last couple of months, which is expected to drive further growth.

VCEL

USD 35.68

-5.31%

A-Score: 3.4/10

Publication date: February 26, 2026

Full Report

Author: Analystock.ai

šŸ“‹ Highlights
  • Record Q4 Revenue Growth: Vericel reported $92.9M in Q4 2025 revenue, a 23% YoY increase, driven by MACI revenue of $84.1M (23% YoY, 51% sequential growth).
  • Strong Full-Year 2025 Performance: Total revenue reached $276.3M, with MACI contributing $239.5M (21% YoY growth) and Burn Care $36.8M.
  • 2026 Revenue Guidance: Projects $316ā€“326M total revenue, with MACI expected to grow 20% to $280ā€“286M and Burn Care at $36ā€“40M.
  • Margin Adjustments: Gross margin is projected to decline to 75% in 2026 from 79% in Q4 2025 due to new manufacturing costs, despite strong adjusted EBITDA of 40% in Q4.
  • Sales Force Expansion & Surgeon Training: A 30% sales force increase and 1,000 trained surgeons for MACI Arthro drove volume growth, supporting 20%+ MACI franchise growth in 2026.

Guidance and Strategic Imperatives for 2026

For 2026, Vericel expects total revenue of $316 million to $326 million, with MACI revenue projected to be $280 million to $286 million. The company has outlined three strategic imperatives for 2026: capitalizing on the larger MACI sales force, leveraging MACI Arthro to drive growth in smaller cartilage defects, and advancing life cycle management initiatives. The guidance for MACI is around 20% growth, which is in line with analyst expectations. The company feels good about the start of the year, with MACI metrics being strong and Burn Care having a strong start as well. Analysts estimate next year's revenue growth at 18.0%, indicating a consistent growth trajectory.

Operational Highlights and Margin Expectations

The company has expanded its sales force and expects rep productivity to return to last year's level quickly. The new sales force expansion will increase the company's reach across the surgeon base and drive expansion of surgeons and deeper penetration in existing surgeons. Regarding gross margin, the company reported 79% in Q4 2025 but guided for 75% in 2026 due to additional costs associated with the new manufacturing facility in Burlington and depreciation. The company anticipates OpEx of approximately $220 million for the full year, with $55 million per quarter, mainly driven by the expansion of the sales force and incremental costs associated with the Ankle trial.

Valuation and Growth Prospects

With a P/E Ratio of 109.28 and an EV/EBITDA of 60.57, the market appears to have priced in significant growth expectations for Vericel Corporation. The company's ROE is 5.17%, and ROIC is 2.32%, indicating a decent return on equity but a relatively lower return on invested capital. The Net Debt / EBITDA ratio is -0.13, highlighting the company's net cash position. As Vericel looks forward to sustained high revenue growth and profitability in 2026 and beyond, driven by MACI and Burn Care, the current valuation metrics suggest that the stock may be priced for high expectations, and investors will be watching closely to see if the company can deliver on its growth promises.

Vericel's A-Score